Poteligeo
Poteligeo ingredients
| Active ingredient | Strength |
|---|---|
| Mogamulizumab | 4 mg/mL |
What Poteligeo is used for
The FDA lists the approved uses on the official label (below). In the EU, mogamulizumab is approved as Poteligeo for:
Poteligeo is indicated for the treatment of adult patients with mycosis fungoides (MF) or Sézary syndrome (SS) who have received at least one prior systemic therapy.
EU wording from the European Medicines Agency; US approved uses can differ.
Key facts
- Brand
- Poteligeo
- Generic name
- Mogamulizumab-kpkc
- Made by
- Kyowa Kirin, Inc.
- Forms
- Injection
- Given
- Intravenous
- Drug class
- Chemokine Receptor Type 4 Interaction, Monoclonal Antibody
- FDA approval
- Biologic licence (BLA) BLA761051
- On the US market since
- 2018
Official information
- MedlinePlus drug information (search for Mogamulizumab-kpkc)
Specialist medicine: started and supervised by a specialist doctor or hospital. This page is a plain-language summary of public official information, not medical advice; follow your doctor and the official product information.
Common questions
What is Poteligeo?
Poteligeo (Mogamulizumab-kpkc) is a cancer medicine made by Kyowa Kirin, Inc., approved by the US FDA.
What are the ingredients of Poteligeo?
Poteligeo contains Mogamulizumab (4 mg/mL).
Is Poteligeo approved in Europe?
The same active substance is approved in the EU as Poteligeo.
From the FDA National Drug Code directory (open.fda.gov, public domain) and the European Medicines Agency medicines list. Page made 5 November 2026 by Satya Babu.
← All specialty medicines, USA